newsfilter
← Latest News
Business Wire·

Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

Funds to advance ATI-1701 to IND submission Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Department of Def